Latest KFF Health News Stories
Podcast: KHN’s ‘What The Health?’ ‘Conscience’ Rules, Rx Prices and Still More Medicare
Joanne Kenen of Politico, Jen Haberkorn of the Los Angeles Times and Alice Miranda Ollstein of Politico join KHN’s Julie Rovner to discuss the latest news about the Trump administration’s effort to allow health care practitioners and organizations to refuse to provide care or refer patients for services that violate their conscience or religion. Also this week, the administration orders TV ads for prescription drugs to include list prices. And Tennessee wants free rein from the federal government to run its Medicaid program. Plus, Rovner interviews Joan Biskupic, author of a new book on Chief Justice John Roberts, about the behind-the-scenes negotiations that led to the 2012 ruling upholding the constitutionality of the Affordable Care Act.
Price Check On Drug Ads: Would Revealing Costs Help Patients Control Spending?
As part of his plan to tamp down drug pricing, President Donald Trump wants pharmaceutical companies to provide cost information in drug ads — just like side effects.
The Money And Politics Of Prescription Drugs: What You Need To Know
America spends about as much on prescription drugs as all the revenues of the three big car makers combined. Tracking where the money goes is hard. PolitiFact has some charts to help.
Drug Industry Patents Go Under Senate Judiciary Committee’s Microscope
During a hearing Tuesday, panel members focused on how drug companies have used patents to allegedly protect their competitive edge and profits.
Is Insulin’s High Cost Keeping Diabetes Patients From Taking Their Medicine?
An estimated 1.25 million Americans have Type 1 diabetes and cannot live without insulin. Sen. Kamala Harris’ claim that 1 in 4 diabetes patients cannot afford their insulin is a shockingly high number, so we decided to dig into the sparse data.
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health care policy stories each week, so you don’t have to.
Newsom: California Leads On Prescription Drugs
California Gov. Gavin Newsom claims that his state is “leading the nation in holding drug companies accountable and fighting prescription drug prices.” Is that really the case?
Klobuchar Wants To Stop ‘Pay-For-Delay’ Deals That Keep Drug Prices High
It’s as shady as it sounds.
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don’t have to.
Mulvaney: Trump Brought Down Drug Prices For The First Time In 50 Years
It’s “within spitting distance of something that’s true,” said one health economist. But our fact check found it wasn’t quite there.
Podcast: KHN’s ‘What The Health?’ Still More ‘Medicare-For-All’
Sarah Kliff of Vox.com, Margot Sanger-Katz of The New York Times and Paige Winfield Cunningham of The Washington Post join KHN’s Julie Rovner to discuss the latest version of a “Medicare-for-all” bill by Sen. Bernie Sanders (I-Vt.), a presidential hopeful, and Democratic and Republican reactions to it. They also discuss the latest on congressional efforts to rein in drug prices and another state effort to expand Medicaid — but not exactly in the way voters wanted. Also, Rovner interviews Ceci Connolly of the Alliance of Community Health Plans.
The Blame Game: Everyone And No One Is Raising Insulin Prices
During Wednesday’s House subcommittee hearing on insulin price hikes, drug makers and benefits managers pointed fingers at each other for the last decade’s 300% price increase, frustrating congressional representatives.
Can Someone Tell Me What A PBM Does?
The Senate Finance Committee’s third drug-pricing hearing focused on pharmacy benefit managers, and was more of a fact-finding mission on how these companies operate than a debate about policy proposals.
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don’t have to.
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don’t have to.
Analysis: Why Americans Shouldn’t Feel Grateful For $137 Insulin
Only by the bizarre logic of the U.S. pharmaceutical industry does this drug count as any kind of generic.
Must-Reads Of The Week (Some Flying Below The Radar)
Executive editor Damon Darlin takes a spin as host of “The Friday Breeze,” whirling through a week of health care news so you don’t have to.
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don’t have to.
Podcast: KHN’s ‘What The Health?’ The Karma Of Cutting Medicare
Stephanie Armour of The Wall Street Journal, Alice Ollstein of Politico and Rebecca Adams of CQ Roll Call join KHN’s Julie Rovner to discuss the suggested cuts to health programs in President Donald Trump’s budget proposal, the latest on lawsuits challenging work requirements for Medicaid enrollees and the FDA’s crackdown on e-cigarettes. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week.
How Much Difference Will Eli Lilly’s Half-Price Insulin Make?
Eli Lilly released a half-price generic version of its own short-acting insulin. At $137.35 per vial, the generic insulin is priced at about the same level as Humalog was in 2012.
